TrialPath
Recruiting

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326 · Sundance Biosciences, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
About this study
This Phase 2a, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and impact on measures of neuroinflammation in the central nervous system (CNS) of SUN-627 administered at 2 dose levels in participants with non-active SPMS/PPMS.
Eligibility criteria
Inclusion Criteria: 1. Aged 18-70, inclusive 2. Diagnosis of PPMS or non-active SPMS 3. No MS relapses in the past 2 years 4. Evidence that MS has continued to get worse over time 5. A level of disability that fits the study requirements Exclusion Criteria: 1. Use of certain medications or treatments before the study, or need for these treatments during the study 2. Current participation in another research study 3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk 4. Certain serious or unstable medical conditions that could make the study unsafe 5. Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study protocol.
Study design
Enrollment target: 20 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-10
Estimated completion: 2027-07
Last updated: 2026-10-30
Interventions
Drug: SUN-627Other: Placebo
Primary outcomes
  • • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo (From enrollment to the end of study at 16 weeks)
Sponsor
Sundance Biosciences, Inc. · industry
Contacts & investigators
ContactChetan Gandhy, MD · contact · clinicaltrials@sundancebio.com · 650-442-3187
All locations (7)
Local Institution - Site 103Recruiting
Tampa, Florida, United States
Local Institution - Site 102Recruiting
Atlanta, Georgia, United States
Local Institution - Site 106Not Yet Recruiting
Stony Brook, New York, United States
Local Institution - Site 101Recruiting
Raleigh, North Carolina, United States
Local Institution - Site 104Recruiting
Columbus, Ohio, United States
Local Institution - Site 105Recruiting
Oklahoma City, Oklahoma, United States
Local Institution - Site 107Not Yet Recruiting
Dallas, Texas, United States